Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis
Open Access
- 20 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Respiratory Research
- Vol. 21 (1), 1-11
- https://doi.org/10.1186/s12931-020-1329-y
Abstract
Although phosphodiesterase-4 (PDE4) inhibitors have been shown to reduce COPD exacerbation rate, their biological mechanism of action is not completely elucidated at the molecular level. We aimed to characterise the whole genome gene expression profile of the inhaled PDE4-inhibitor CHF6001 on top of triple therapy in sputum cells and whole blood of patients with COPD and chronic bronchitis. Whole genome gene expression analysis was carried out by microarray in 54 patients before and after 32 days treatment with CHF6001 800 and 1600 μg and placebo twice daily (BID) in a randomised crossover study. CHF6001 had a strong effect in sputum, with 1471 and 2598 significantly differentially-expressed probe-sets relative to placebo (p-adjusted for False Discovery Rate < 0.05) with 800 and 1600 μg BID, respectively. Functional enrichment analysis showed significant modulation of key inflammatory pathways involved in cytokine activity, pathogen-associated-pattern-recognition activity, oxidative stress and vitamin D with associated inhibition of downstream inflammatory effectors. A large number of pro-inflammatory genes coding for cytokines and matrix-metalloproteinases were significantly differentially expressed for both doses; the majority (> 87%) were downregulated, including macrophage inflammatory protein-1-alpha and 1-beta, interleukin-27-beta, interleukin-12-beta, interleukin-32, tumour necrosis factor-alpha-induced-protein-8, ligand-superfamily-member-15, and matrix-metalloproteinases-7,12 and 14. The effect in blood was not significant. Inhaled PDE4 inhibition by CHF6001 on top of triple therapy in patients with COPD and chronic bronchitis significantly modulated key inflammatory targets and pathways in the lung but not in blood. Mechanistically these findings support a targeted effect in the lung while minimising unwanted systemic class-effects. ClinicalTrial.gov, EudraCT, 2015–005550-35. Registered 15 July 2016.Funding Information
- Chiesi Farmaceutici (N/A)
This publication has 54 references indexed in Scilit:
- IL-13–induced airway mucus production is attenuated by MAPK13 inhibitionJCI Insight, 2012
- Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPDRespiratory Research, 2011
- A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseasesExpert Opinion on Investigational Drugs, 2011
- Deletion of vitamin D receptor leads to premature emphysema/COPD by increased matrix metalloproteinases and lymphoid aggregates formationBiochemical and Biophysical Research Communications, 2011
- Neutrophil elastase inhibitorsExpert Opinion on Therapeutic Patents, 2011
- Sphingolipid-mediated Inhibition of Apoptotic Cell Clearance by Alveolar MacrophagesOnline Journal of Public Health Informatics, 2010
- The cytokine network in asthma and chronic obstructive pulmonary diseaseJCI Insight, 2008
- Oxidative Stress, Plasminogen Activator Inhibitor 1, and Lung FibrosisAntioxidants and Redox Signaling, 2008
- Effects of CXCL10 on Dendritic Cell and CD4+T-Cell Functions duringLeishmania amazonensisInfectionInfection and Immunity, 2008
- Soluble Triggering Receptor Expressed on Myeloid Cells 1 Is Released in Patients with Stable Chronic Obstructive Pulmonary DiseaseJournal of Immunology Research, 2007